Intranasal Naloxone (NS -001)
in 2017 ~72000 overdose death in the USA~42000 from opioids.
current treatment is Naloxone ( IM or IV ) and recently intranasal. Narcan first solution-based intranasal therapy approved in 2017 first generic (Teva) approved 2019
bioequivalence study –”equal or better”
“Eyeing $1B in annual sales, Emergent Bio Solutions to buys Narcan maker Adapt for $735M (9/2018)”
NS – 001 VS Narcan